Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.
Arthritis Knee Pain Centers
2 followers
Harrison.ai
3 followers
AstraZeneca
460 followers
Bayer
377 followers
Bristol-Myers Squibb
275 followers
UCB
67 followers
Astellas Pharma
45 followers
NYU Langone Health
34 followers
Tilray
19 followers
Perrigo
17 followers
West Pharmaceutical Services
9 followers
Explore companies